Clinical prognostic value of circulating tumor cells in the treatment of pancreatic cancer with gemcitabine chemotherapy
Open Access
- 8 August 2021
- journal article
- research article
- Published by Spandidos Publications in Experimental and Therapeutic Medicine
- Vol. 22 (4) , 1-11
Abstract
Pancreatic cancer (PC) is a highly malignant tumor type with a high early metastasis rate and no obvious symptoms. Gemcitabine is a first‑line chemotherapeutic drug for PC. Since there is no distinct method to determine the efficacy of chemotherapy with gemcitabine in patients with PC, the purpose of the present study was to determine whether positivity for circulating tumor cells (CTCs) in patients with advanced PC is associated with response to gemcitabine chemotherapy and to explore whether CTCs may be used as a predictor of prognosis of patients with advanced PC undergoing chemotherapy. First, immunomagnetic microspheres (magnetic beads; MIL) were prepared to detect CTCs. The patients' clinical characteristics and survival data, as well as efficacy and adverse effects of chemotherapy, were prospectively obtained and their association with CTCs was analyzed. The results indicated that CTC‑positive patients with advanced PC had a higher probability of developing resistance to gemcitabine chemotherapy than CTC‑negative patients. Survival in the CTC‑negative group was significantly higher than in the CTC‑positive group (χ2=14.58, P<0.001). CTC‑positive patients with advanced PC also had shorter progression‑free survival (PFS) after chemotherapy with gemcitabine (P=0.01). In conclusion, CTC‑positive patients with PC are more likely to develop gemcitabine resistance, have poor PFS and low incidence of thrombocytopenia. CTCs are expected to become a prognostic indicator for chemotherapy response in patients with PC.Keywords
This publication has 39 references indexed in Scilit:
- Translating metastasis-related biomarkers to the clinic—progress and pitfallsNature Reviews Clinical Oncology, 2013
- Circulating Breast Tumor Cells Exhibit Dynamic Changes in Epithelial and Mesenchymal CompositionScience, 2013
- Gemcitabine Plusnab-Paclitaxel Is an Active Regimen in Patients With Advanced Pancreatic Cancer: A Phase I/II TrialJournal of Clinical Oncology, 2011
- Clinical Significance of Circulating Tumor Cells, Including Cancer Stem-Like Cells, in Peripheral Blood for Recurrence and Prognosis in Patients With Dukes' Stage B and C Colorectal CancerJournal of Clinical Oncology, 2011
- Metastatic pancreatic cancer: Is gemcitabine still the best standard treatment? (Review)Oncology Reports, 2010
- Novel Quaternized Chitosan and Polymeric Micelles With Cross-Linked Ionic Cores for Prolonged Release of MinocyclineJournal of Biomaterials Science, Polymer Edition, 2009
- Surgical Treatment of Pancreatic CancerAnnals of the New York Academy of Sciences, 2008
- Detection of circulating tumor cells in patients with pancreatic cancer: a preliminary resultJournal of Hepato-Biliary-Pancreatic Surgery, 2008
- CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatmentSeminars in Radiation Oncology, 2003
- A phase II trial of gemcitabine in patients with 5-FU-refractory pancreas cancerAnnals of Oncology, 1996